

## DAFTAR PUSTAKA

1. Diana R, Rahayu T, Wirawan E, Dhamayanti M, Irawanto ME. Pathophysiology and management of stevens-johnson syndrome and toxic epidermal necrolysis. *J Gen Dermatology Venereol Indones*. 2020;5(1):28–39.
2. Hermiaty, Syamsu RF, Diana NA. Penanganan dan preventif sindrom stevens johnson di masyarakat. *Cerdika J Ilm Indones*. 2021;1(2):120–37.
3. Kusuma AE, Anggraini DI. Sindrom stevens-johnson (ssj) melebihi nekrolisis epidermal toksik (net) pada geriatri : laporan kasus. *Medula*. 2020;10(2):380–7.
4. Djuanda A. Sindrom stevens-johnson: ilmu penyakit kulit dan kelamin. 6th ed. Jakarta: Fakultas Kedokteran Universitas Indonesia; 2011.
5. Tan SK, Tay YK. Profile and pattern of stevens-johnson syndrome and toxic epidermal necrolysis in a general hospital in singapore: treatment outcomes. *Acta Derm Venereol*. 2012;92(1):62–6.
6. Yang SC, Hu S, Zhang SZ, et al. The epidemiology of stevens-johnson syndrome and toxic epidermal necrolysis in china. *J Immunol Res*. 2018;
7. Novi Diana ED, Tri Irfanti R, Rahma A, - F, Nugraha W, Eko Irawanto M. Terapi kortikosteroid sistemik untuk sindrom steven johnson (ssj)- nekrolisis epidermal toksik (net) di rsud dr moewardi, surakarta, indonesia. *Cermin Dunia Kedokt*. 2021;48(4):215.
8. Carvalho MR De, Rita M, Garbi C, Novaes AG, Bernarda L, Göttems D. Epidemiological and clinical outcomes analysis in public hospitals. *An Bras Dermatol*. 2017;92(5):661–7.
9. Patel TK, Barvaliya MJ, Sharma D, Tripathi C. A systematic review of the drug-induced stevens-johnson syndrome and toxic epidermal necrolysis in indian population. *Indian J Dermatol Venereol Leprol*. 2013;79(3):389–98.
10. Alerhand S, Cassella C, Koyfman A. Stevens-johnson syndrome and toxic epidermal necrolysis in the pediatric population: a review. *Pediatr Emerg Care*. 2016;32(7):472–6.
11. Devinta E, Irfanti RT, Rahma A, Frieda, Nugraha W, Irawanto ME. Terapi kortikosteroid sistemik untuk sindrom steven johnson (ssj)-nekrolisis epidermal toksik (net) di rsud dr moewardi, surakarta, indonesia. 2021;48(4):215–8.
12. Rahayu A, Gustia R, Rahmatini R. Profil sindrom stevens johnson pada pasien rawat inap di rsup dr. m. djamil padang periode januari 2010 sampai desember 2011. *J Kesehat Andalas*. 2014;3(2):110–3.
13. Sudarsa PSS, Puspawati NMD, Purnami NKR, Sanjaya IGPH, Hamid ARRH. Toxic epidermal necrolysis (ten) in an elderly with comorbidities: a case report. *Bali Med J*. 2020;9(1):323–6.
14. Harr T, French LE. Toxic epidermal necrolysis and stevens-johnson

- syndrome. *Orphanet J Rare Dis.* 2010;5.
15. Laurence VA, J C. Epidermal necrolysis (stevens-johnson syndrome and toxic epidermal necrolysis). dalam: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editor. *fitzpatrick's dermatology in general medicine.* 8th ed. Amerika Serikat: McGraw-Hill; 2012. 439–448 p.
  16. Wong A, Malvesiti A, Hafner M. Stevens-johnson syndrome and toxic epidermal necrolysis. *Rev Assoc Med Brass.* 2016;62(5):468–73.
  17. Kementrian Kesehatan Republik Indonesia. Analisis lansia indonesia. Kemenkes RI. 2017.
  18. Turana Y MM. panduan program simulasi otak pada Lansia. Nida Dwi Karya. 2013.
  19. Mawarni EE. Prinsip gizi pada lansia: gizi dalam daur kehidupan. Oktavianis, Maida R, editors. Padang: PT. Global Eksekutif Teknologi; 2022.
  20. Carvalho MR De, Rita M, Garbi C, Novaes AG, Bernarda L, Göttems D. epidemiological and clinical outcomes analysis in public hospitals \*. *2017;92(5):661–7.*
  21. Fitriany J, Alratidsa F. Stevens johson syndrome. *J Averrous.* 2019;5.
  22. Nirken MH. Steven-johnson syndrome and toxic epidermal necrolysis : pathogenesis, clinical manifestations and diagnosis. MD Empl UpToDate Inc. 2015;
  23. Maria J T, Christobalina M, Miguel B. Nonimmediate allergic reactions induced by drugs: pathogenesis and diagnostic test. *J Investig Allergol Clin Immunol.* 2009;
  24. Micheletti RG, Chiesa-fuxench Z, Noe MH, Stephen S, Aleshin M, Agarwal A, et al. Stevens-johnson syndrome/toxic epidermal necrolysis : a multicenter retrospective study of 377 adult patients from the united states. *J Invest Dermatol.* 2018;138(11):2315–21.
  25. Haur Y L, Wijaya M, Thamothersampillai T. Epidemiology of stevens–johnson syndrome and toxic epidermal necrolysis in southeast asia. *Dematologica Sin.* 2013;4(31):217–20.
  26. Anwar AND, Carolia N, Hamzah MS. Stevens johnson syndrome - toxic epidermal necrolysis overlap disebabkan oleh drug eruption obat anti tuberkulosis. *Med Fac Lampung Univ.* 2017;7(9):8–14.
  27. Effendi E H. Sindrom stevens johnson dan nekrolisis epidermal toksik. dalam: menaldi sls editor. *ilmu penyakit kulit dan kelamin.* 7th ed. Jakarta: Fakultas Kedokteran Universitas Indonesia; 2017. 199–200 p.
  28. Isaac WA, Damayanti D, Fatimah N, Hidayati AN. The profiles of stevens-johnson syndrome (sjs) and toxic epidermal necrolysis (ten) patients in tertiary hospital. *Berk Ilmu Kesehat Kulit dan Kelamin.* 2021;33(2):116.
  29. Suwarsa O, Yuwita W, Purbo H, Sutedja E. Stevens-Johnson syndrome and toxic epidermal necrolysis in dr. hasan sadikin general hospital bandung,

- indonesia from 2009–2013. *Asia Pac Allergy*. 2016;6:43–7.
30. Ng CY, Chen CB, Wu MY, Wu J, Yang CH, Hui RCY, et al. Anticancer drugs induced severe adverse cutaneous drug reactions: an updated review on the risks associated with anticancer targeted therapy or immunotherapies. *J Immunol Res*. 2018;
  31. N S. Stevens-Johnson Syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy. *Am J Clin Dermatol*. 2009;10(4):264–7.
  32. Gillis NK, Hicks JK, Bell GC, Daly AJ, Kanetsky PA, McLeod HL. Incidence and triggers of stevens-johnson syndrome and toxic epidermal necrolysis in a large cancer patient cohort. *J Invest Dermatol*. 2017;137(9):2021–3.
  33. Rebecca L T, Whitney V T, John T O, Karen R B, Maria C G, Philip L, et al. Influenza b virus infection and stevens–johnson syndrome. *Pediatr Dermatol*. 2018;35(1):45–8.
  34. Hazin R, Ibrahim OA, Hazin MI, Kimyai-Asadi A. Stevens-johnson syndrome: pathogenesis, diagnosis, and management. *Ann Med*. 2008;40(2):129–38.
  35. Chahal D, Aleshin M, Turegano M, Chiu M, Worswick S. Vaccine-induced toxic epidermal necrolysis: a case and systematic review. *Dermatol Online J*. 2018;24(1):0–10.
  36. Gravante G, Delogu D, Marianetti M, Trombetta M, Esposito G, Montone A. Toxic epidermal necrolysis and steven johnson syndrome: 11-years experience and outcome. *Eur Rev Med Pharmacol Sci*. 2007;11(2):119–27.
  37. Li W, Xue-Ling M. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 88 Chinese patients. 2017;130(9):1062–8.
  38. Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of stevens-johnson syndrome and toxic epidermal necrolysis in united states adults. *J Invest Dermatol*. 2016;136(7):1387–97.
  39. C A. Stevens-johnson syndrome: drug alert. *JIPMER*. India; 2006.
  40. Mansjoer A, Suprohaita, Wardhani WI SW. Erupsi alergi obat. dalam: kapita selekta kedokteran. 3rd ed. Jakarta: Fakultas Kedokteran Universitas Indonesia. Media Aesculapius; 2000. 135–139 p.
  41. Roni P DG, Wen-Hung C, Laurence VA, Neil H S. Stevens–Johnson syndrome and toxic epidermal necrolysis: an update. *Am J Clin Dermatol*. 2015;16(6):457–93.
  42. Grace O, Laurence VA, Pierre W. Toxic epidermal necrolysis (ten) and stevens-johnson syndrome (sjs). in european handbook of dermatological treatments (pp. 971-982). Springer Berlin Heidelb. 2015;
  43. Mockenhaupt M. The current understanding of stevens-johnson syndrome and toxic epidermal necrolysis. *Expert Rev Clin Immunol*. 2011;7(6):803–15.



44. Dean S E, James J D, Andre A M, Marc M. Unusual manifestation of stevens-johnson syndrome involving the respiratory and gastrointestinal tract. *Pediatrics*. 1992;89(3):429–32.
45. Marianne L, Carlo M, Benedetta TBP, Harr T. Current perspectives on stevens-johnson syndrome and toxic epidermal necrolysis. *Clin Rev Allerg Immunol*. 2018;54:147–76.
46. Yasuyuki F, Naoya Y, Riichiro A, Junko M, Daichi H, Hirokatsu M, et al. Rapid immunochromatographic test for serum granulysin is useful for the prediction of stevens-johnson syndrome and toxic epidermal necrolysis. *J Am Acad Dermatol*. 2011;65(1):65–8.
47. Knowles S, Shear NH. Clinical risk management of stevens-johnson syndrome/toxic epidermal necrolysis spectrum. *Dermatol Ther*. 2009;22(5):441–51.
48. Whitney A H, Roujeau J. Stevens-johnson syndrome and toxic epidermal necrolysis: management, prognosis, and long-term sequelae. UpToDate [Internet]. Waltham (MA): UpToDate. 2017.
49. Yim H, Park JM, Cho YS, Kim D. A clinical study of stevens-johnson syndrome and toxic epidermal necrolysis: efficacy of treatment in burn intensive care Unit. *J Korean Surg Soc*. 2010;133–9.
50. Brent M. The role of systemic corticosteroid therapy in erythema multiforme major and stevens-johnson syndrome: a review of past and current opinions. *J Clin Aesthet Dermatol*. 2009;2.
51. Alan D W. Toxic epidermal necrolysis-management issues and treatment options. *Int J Burns Trauma*. 2011;1.
52. Olteanu C, Shear NH, Chew HF, Hashimoto R, Alhusayen R, Whyte-Croasdaile S, et al. Severe physical complications among survivors of stevens-johnson syndrome and toxic epidermal necrolysis. *Drug Saf*. 2018;41(3):277–84.
53. Yip LW, Thong BY, Lim J, Tan AW, Wong HB, Handa S, et al. Ocular manifestations and complications of stevens-johnson syndrome and toxic epidermal necrolysis: an asian series. *Allergy Eur J Allergy Clin Immunol*. 2007;62(5):527–31.
54. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. Scorten: a severity-of-illness score for toxic epidermal necrolysis. *J Invest Dermatol*. 2000;115(2):149–53.
55. Fatmah. Gizi usia lanjut. Jakarta: Erlangga; 2010. 16–33 p.
56. Cunningham. WJ. Textbook of cosmetic dermatology. 2nd ed. Baran R, Maibach HI, editors. Martin Dunitz; 1998.
57. Novita W S, Tria F, Yusuf A, Tantri S. Gerakan lansia anti osteoporosis di dusun lempuyangan desa gebugan kecamatan bergas kabupaten semarang. *J Pengabd Masy Sisthana*. 2020;2(1):22–9.
58. Mickey S, Patricia Gauntlett B. Buku ajar keperawatan gerontik. 2nd ed.

- Jakarta: EGC; 2007.
59. Wahyudi N. Keperawatan gerontik edisi 2. 2nd ed. Jakarta: EGC; 2000.
  60. Yenny SW, Suryani YE. Polyphenols as Natural Antioxidants in Skin Aging. *Sumatera Med J.* 2020;3(3):1–8.
  61. F H. Teori dan praktek keperawatan. Jakarta: EGC; 1982.
  62. Winsy F. Th Warouw. Manifestasi penyakit sistemik pada kulit usia lanjut : problematika dermatologi geriatri dan penanganannya. Legiawati. Jakarta: Balai Penerbit FKUI; 2009. 26–28 p.
  63. Farage MA, Miller KW, Berardesca E, Maibach HI. Clinical implications of aging skin: cutaneous disorders in the elderly. *Am J Clin Dermatol.* 2009;10(2):73–86.
  64. Simon AK, Hollander GA, Mcmichael A, Mcmichael A. Evolution of the immune system in humans from infancy to old age. 2015;
  65. Soejono CH. Pengkajian paripurna pada pasien geriatri. [book auth.] siti setiati. buku ajar ilmu penyakit dalam jilid III. 6th ed. Jakarta: InternaPublishing; 2015.
  66. Kemenkes RI. Infodatin lansia kemenkes. Departemen Kesehatan. 2016.
  67. Jakovljević M, Ostojić L. Comorbidity and multimorbidity in medicine today: challenges and opportunities for bringing separated branches of medicine closer to each other. *Psychiatr Danub.* 2013;25 Suppl 1(1):18–28.
  68. Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, et al. Aging with multimorbidity: a systematic review of the literature. *Ageing Res Rev.* 2011;10(4):430–9.
  69. Lappenschaar M, Hommersom A, Lucas PJF. Probabilistic causal models of multimorbidity concepts. :475–84.
  70. White KD, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B, et al. SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. *J Allergy Clin Immunol Pract* [Internet]. 2018;6(1):38–69. Available from: <https://doi.org/10.1016/j.jaip.2017.11.023>
  71. Patel S, Radhika S, Sara B, William C L. Increased mortality in elderly patients with stevens-johnson syndrome and toxic epidermal necrolysis. *JAM Acad Dermatol.* 2019;81(4).
  72. Weinand C, Xu W, Perbix W, Lefering R, Maegele M, Rathert M, et al. 27 years of a single burn centre experience with Stevens-Johnson syndrome and toxic epidermal necrolysis: Analysis of mortality risk for causative agents. *Burns.* 2013;39(7):1449–55.
  73. Irungu K, Nyamu D, Opanga S. Characterization of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Among Patients Admitted to Kenyatta National Hospital: A Retrospective Cross-Sectional Study. *Drugs - Real World Outcomes.* 2017;4(2):79–85.
  74. Yuli W R, Diah M I. A retrospective study: stevens-johnson syndrome and

- toxic epidermal necrolysis. *Berk Ilmu Kesehat Kulit dan Kelamin – Period Dermatology Venereol.* 2016;28(2):146–54.
75. Africa R, Mobli K, Hallman T, Schober M, Jason M, Wermine K, et al. 545 pharmacologic and comorbid factors associated with stevens-johnson syndrome and toxic epidermal necrolysis syndrome. *J Burn Care Res.* 2021;42(Supplement\_1).
  76. Carrasquillo OY, Santiago-Vazquez M, Cardona R, Cruz-Manzano M, Figueroa LD. Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective descriptive study. *Int J Dermatol.* 2019;58(11):1293–9.
  77. Sousa-Pinto B, Araújo L, Freitas A, Correia O, Delgado L. Stevens-Johnson syndrome/toxic epidermal necrolysis and erythema multiforme drug-related hospitalisations in a national administrative database. *Clin Transl Allergy [Internet].* 2018;8(1):1–10. Available from: <https://doi.org/10.1186/s13601-017-0188-1>
  78. Tri Irfanti R, Imelda Betaubun A, Fiqri A, Anggraeni R, Rinandari U, Kariosentono H. Profil Penggunaan Kortikosteroid Sistemik untuk Terapi Sindrom Stevens Johnson (SSJ) – Nekrolisis Eepidemal Toksik (NET) di Instalasi Rawat Inap RSUD DR. Moewardi Surakarta, Indonesia - Januari 2016 -Desember 2017. *Cermin Dunia Kedokt.* 2021;48(4):220.
  79. Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. *J Invest Dermatol [Internet].* 2016;136(7):1387–97. Availablefrom: <http://dx.doi.org/10.1016/j.jid.2016.03.023>
  80. Cheng L. Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. *Front Pharmacol.* 2021;12(April):1–17.
  81. Queena Maureen Wijanto J, Damayanti D, Fathul Qorib M, Anggraeni S, Rosita Sigit Prakoeswa C. Risk Factors for Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) in Dr. Soetomo General Hospital Surabaya. *Int J Res Publ.* 2021;92(1):361–8.
  82. Wijaya AM, Herawati F, Yulia R. Kajian Literatur: Efektivitas Antibiotik Golongan Beta-Laktam pada Pasien Lansia dengan Pneumonia Komunitas. *J Sains Farm Klin.* 2021;8(2):80.
  83. Lee H, Wijaya M, Thamotharampillai T. Epidemiology of stevens-johnson syndrome and toxic epidermal necrolysis in southeast asia. *Dermatol Sin.* 2013;4(13):217–20.
  84. Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. *Lancet [Internet].* 2019;393(10167):183–98. Available from: [http://dx.doi.org/10.1016/S0140-6736\(18\)32218-9](http://dx.doi.org/10.1016/S0140-6736(18)32218-9)
  85. Khan DA, Banerji A, Bernstein JA, Bilgicer B, Blumenthal K, Castells M, et al. Cephalosporin Allergy: Current Understanding and Future Challenges. *J Allergy Clin Immunol Pract [Internet].* 2019;7(7):2105–14. Availablefrom: <https://doi.org/10.1016/j.jaip.2019.06.001>

86. Chatproedprai S, Wutticharoenwong V, Tempark T, Wananukul S. Clinical Features and Treatment Outcomes among Children with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A 20-Year Study in a Tertiary Referral Hospital. *Dermatol Res Pract*. 2018;2018(316).
87. Dewi CC. Tinjauan atas stevens-johnson syndrome dan toxic epidermal necrolysis. *Cermin Dunia Kedokt* [Internet]. 2019;46(7):55–9. Available from: <http://www.cdkjournal.com/index.php/CDK/article/view/457>
88. Das S, Roy AK, Indranil B. A six month prospective study to find out the treatment outcome, prognosis and offending drugs in toxic epidermal necrolysis from an urban institution in kolkata. *Indian J Dermatol*. 2013;58(3):191.
89. Sunaga Y, Hama N, Ochiai H, Kokaze A, Lee ES, Watanabe H. Risk factors for sepsis and effects of pretreatment with systemic steroid therapy for underlying condition in sjs/ten patients: results of a nationwide cross-sectional survey in 489 japanese patients. *J Dermatol Sci*. 2022;107(2):75–81.

